VX-118

VX-118 is an investigational small molecule drug under development by Vertex Pharmaceuticals for the treatment of cystic fibrosis. It is administered orally and available in tablet and suspension formulations. As of early 2025, VX-118 has completed Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and the effect of food on its bioavailability in healthy participants. The precise mechanism of action for VX-118 has not been publicly disclosed; it is described as having an unknown mechanism and does not represent a novel mechanistic class according to current sources. Vertex Pharmaceuticals specializes in therapies for cystic fibrosis and other serious diseases.